DCST1-AS1: A Promising Drug Target / Biomarker (G100505666)
DCST1-AS1: A Promising Drug Target / Biomarker
DCST1-AS1 is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the superfamily of cytoskeletal proteins, which are involved in the structure and function of cells. DCST1-AS1 has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and respiratory diseases.
The Protein Structure and Functions
DCST1-AS1 is a 21-kDa protein that consists of 156 amino acid residues. It has a molecular weight of 19.9 kDa and a calculated pI of 1.57. DCST1-AS1 is expressed in various tissues of the body and is involved in the development, maintenance, and regulation of tissue structure and function.
One of the unique features of DCST1-AS1 is its cytoskeleton-like structure. It consists of a series of beta-strands that are arranged in a repeating pattern of alternating between beta-helices and beta-strands. The beta-helices are composed of a series of amino acids that are involved in the formation of a beta-sheet, which is a common structural unit in proteins. The beta-sheet is connected to the cytoskeleton by a series of alpha-helices, which are also involved in the formation of the beta-sheet.
The cytoskeleton-like structure of DCST1-AS1 is important for its function in the development and maintenance of tissue structure. It is involved in the regulation of cell adhesion, migration, and the organization of tissues. DCST1-AS1 has been shown to play a role in the development and maintenance of the blood-brain barrier, which is responsible for the exchange of nutrients, oxygen, and other substances between the brain and the bloodstream.
In addition to its role in tissue structure and function, DCST1-AS1 is also involved in the regulation of cellular processes. It is a regulator of the cytoskeleton, which is responsible for the proper alignment and movement of cells. It is also involved in the regulation of cell cycle progression, DNA replication, and apoptosis.
The Potential as a Drug Target
The potential use of DCST1-AS1 as a drug target or biomarker is due to its unique structure and functions. DCST1-AS1 has been shown to play a role in the development and maintenance of various diseases, including cancer, neurodegenerative diseases, and respiratory diseases.
One of the potential mechanisms by which DCST1-AS1 can be targeted as a drug is its role in the regulation of the blood-brain barrier. DCST1-AS1 has been shown to play a role in the development and maintenance of the blood-brain barrier, which is responsible for the exchange of nutrients, oxygen, and other substances between the brain and the bloodstream. By targeting DCST1-AS1, researchers may be able to develop drugs that can cross the blood-brain barrier and target processes that are not accessible to conventional therapies.
In addition to its role in the blood-brain barrier, DCST1-AS1 is also involved in the regulation of cellular processes that are important for the development and maintenance of tissues. It is a regulator of the cytoskeleton, which is responsible for the proper alignment and movement of cells. It is also involved in the regulation of cell cycle progression, DNA replication, and apoptosis. By targeting DCST1-AS1, researchers may be able to develop drugs that can disrupt these processes and lead to the death of cancer cells, neurodegenerative diseases, and respiratory diseases.
DCST1-AS1 has also been shown to play a role in the regulation of various signaling pathways that are involved in the development and maintenance of tissues. It is involved in the regulation of
Protein Name: DCST1 Antisense RNA 1
The "DCST1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DCST1-AS1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
DCST2 | DCSTAMP | DCT | DCTD | DCTN1 | DCTN1-AS1 | DCTN2 | DCTN3 | DCTN4 | DCTN5 | DCTN6 | DCTPP1 | DCUN1D1 | DCUN1D2 | DCUN1D3 | DCUN1D4 | DCUN1D5 | DCX | DCX (DDB1-CUL4-X-box) E3 protein ligase complex | DCX DET1-COP1 ubiquitin ligase complex | DCX(DCAF15) E3 protein ligase complex | DCXR | DDA1 | DDAH1 | DDAH2 | DDB1 | DDB2 | DDC | DDC-AS1 | DDD core complex | DDHD1 | DDHD2 | DDI1 | DDI2 | DDIAS | DDIT3 | DDIT4 | DDIT4L | DDN | DDO | DDOST | DDR1 | DDR2 | DDRGK1 | DDT | DDTL | DDX1 | DDX10 | DDX11 | DDX11-AS1 | DDX11L1 | DDX11L10 | DDX11L2 | DDX11L8 | DDX11L9 | DDX12P | DDX17 | DDX18 | DDX18P1 | DDX19A | DDX19A-DT | DDX19B | DDX20 | DDX21 | DDX23 | DDX24 | DDX25 | DDX27 | DDX28 | DDX31 | DDX39A | DDX39B | DDX39B-AS1 | DDX3P1 | DDX3X | DDX3Y | DDX4 | DDX41 | DDX42 | DDX43 | DDX46 | DDX47 | DDX49 | DDX5 | DDX50 | DDX50P1 | DDX51 | DDX52 | DDX53 | DDX54 | DDX55 | DDX56 | DDX59 | DDX59-AS1 | DDX6 | DDX60 | DDX60L | DDX6P1 | DEAF1 | Death-associated protein kinase
